Caribou Biosciences financials
$1.24+0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M |
| Gross profit | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M | -$67.0M |
| Net income | -$148.3M | -$148.9M | -$102.1M | -$99.4M | -$66.9M |
| Net margin | −1328.8% | −1489.7% | −296.1% | −717.8% | −697.3% |
| Diluted EPS | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 |
| EBITDA | -$132.5M | -$162.7M | -$112.5M | -$104.8M | -$66.0M |
| Operating cash flow | -$111.0M | -$138.2M | -$93.3M | -$91.6M | -$32.5M |
| Free cash flow | -$112.4M | -$143.1M | -$104.9M | -$98.0M | -$35.6M |
| Diluted shares | 93.4M | 90.3M | 73.8M | 60.8M | 31.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $12.4M | $16.3M | $51.2M | $58.3M | $240.4M |
| Short-term investments | $127.0M | $193.2M | $277.7M | $189.3M | $135.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $4.1M |
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | $54.5M |
| Shareholders' equity | $122.2M | $253.0M | $368.4M | $300.9M | $387.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology